Prognosis and growth activity depend on patient age in clinical and subclinical papillary thyroid carcinoma

Endocrine Journal

Volumn 61, Issue 3, 2014, Pages 205-213

  Ito, Yasuhiro ^a   Miyauchi, Akira ^a   Kobayashi, Kaoru ^a   Miya, Akihiro ^a  

^a KUMA HOSPITAL   (Japan)

Author keywords

Age; Papillary thyroid carcinoma; Prognostic factor

Indexed keywords

B RAF KINASE;

AGE DISTRIBUTION; BRAF GENE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; CLINICAL FEATURE; CLINICAL INDICATOR; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MOLECULAR PATHOLOGY; ONCOGENE; OUTCOME ASSESSMENT; PAPILLARY MICROCARCINOMA; PATIENT ASSESSMENT; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; THYROID CARCINOMA; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CARCINOMA; CARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84897423991     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0403     Document Type: Review

References (67)

1. Harasch HR, Fransila KO, Wasenlus VM (1985) Occult papillary carcinoma of the thyroid: A "normal" finding in Finland. A systematic autopsy study. Cancer 56: 531-538.
2. Fukunaga FG, Yatani R (1975) Geographic pathology of occult thyroid carcinomas. Cancer 36: 1095-1099.
3. Thorvaldsson SE, Tulimus H, Bjornsson J, Bjamason O (1992) Latent thyroid carcinioma in Iceland at autopsy. Pathol Res Pract 188: 747-750.
4. Takebe K, Date M, Yamamoto Y (1994) Mas screening for thyroid cancer with ultrasonography. KARKINOS 7: 309-317. (In Japanese)
5. Ito Y, Uruno R, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13: 381-388.
6. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, et al. (2010) An observation trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34: 28-35.
7. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, et al. (2013) Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid in press.
8. thed. New York: Willey-Liss.
9. Cady B, Rosai R (1988) An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 104: 947-953.
10. Shaha AR, Loree TR, Shah JP (1994) Intermediaterisk group for differentiated carcinoma of the thyroid. Surgery 116: 1036-1041.
11. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050-1057.
12. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2004) A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastasis and reclassification during the follow-up period. Surgery 135: 139-148.
13. Ito Y, Ichihara K, Masuoka H, Fukushima M, Inoue H, et al. (2010) Establishment of an intraoperartive staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg 34: 2570-2580.
14. Byar DP, Green SB, Dor P, Williams ED, Colon J, et al. (1979) A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group. Eur J Cancer 15: 1033-1041.
15. Lerch H, Schober O, Kuwert T, Saur HB (1997) Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 15: 2067-2075.
16. Mazzaferri EL, Jhang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428.
17. DeGroot LJ, Kaplan EL, McComick M, Straus FH (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71: 414-424.
18. Miccoli P, Minuto MN, Ugolini C, Panicucci E, Massi M, et al. (2008) Papillary thyroid cancer: Pathological parameters as prognostic factors in different classes of age. Otolaryngol Head Neck Surg 138: 200-203.
19. Ito Y, Kudo T, Kobayashi K, Kobayashi K, Miya A (2011) Prognostic factors of papillary thyroid carcinoma vary according to sex and patient age. World J Surg 35: 2684-2690.
20. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al. (2007) Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 31: 2085-2091.
21. Ito Y, Jikuzono T, Higashiyama T, Asahi S, Tomoda C, et al. (2006) Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg 30: 1821-1828.
22. Ito Y, Fukushima M, Higashiyama T, Kihara M, Takamura Y, et al. (2013) Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of N0 papillary thyroid carcinoma. Endocr J 60: 113-117.
23. Sugino I, Kure Y, Iwasaki H, Ozaki O, Mimura T, et al. (1995) Metastases to the regional lymph nodes, lymph node recurrence, and distant metastases in nonadvanced papillary thyroid carcinoma. Surg Today 25: 324-328.
24. Ahuja S, Ernst H, Lenz K (1991) Papillary thyroid carcinoma: occurrence and types of lymph node metastasis. J Endocrinol Invest 14: 543-549.
25. Ito Y, Kihara M, Takamura Y, Kobayashi K, Miya A, et al. (2012) Prognosis and prognostic factors of papillary thyroid carcinoma in patients under 20 years. Endocr J 59: 539-545.
26. Ito Y, Miyauchi A, Kihara M, Takamura Y, Kobayashi K, et al. (2012) Relationship between prognosis of papillary thyroid carcinoma patient and age: a retrospective single-institution study. Endocr J 59: 399-405.
27. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, et al. (2006) Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 30: 780-786.
28. Ito Y, Hirokawa M, Fukushima M, Inoue H, Yabuta H, et al. (2008) Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 32: 1535-1543.
29. Das DK (2005) Age of patients with papillary thyroid carcinoma: Is it a key factor in the development of variants? Gerontology 51: 149-154.
30. Morris LGT, Shaha AR, Tuttle M, Sikora AG, Ganly I (2010) Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 20: 153-158.
31. Falvo L, Catania A, Grilli P, Di Matteo EM, De Antoni E (2004) Treatment of "locally advanced" well-differentiated thyroid carcinomas. Ann Ital Chir 75: 17-21.
32. Falvo L, Giacomelli L, D'Andrea V, Marzullo A, Guerrero G, et al. (2006) Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 72: 438-444.
33. Fukushima M, Ito Y, Hirokawa M, Akasu H, Shimizu K, et al. (2009) Histologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 33: 958-962.
34. Lam AK, Lo CY (2006) Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13: 176-181.
35. Chow SM, Chan JK, Law SC, Tang DL, Ho CM, et al. (2003) Diffuse sclerosing variant of papillary thyroid carcinoma-clinical features and outcome. Eur J Surg Oncol 29: 446-449.
36. Koo JS, Hong S, Park CS (2009) Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid 19: 1225-1231.
37. Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, et al. (2004) Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 28: 886-889.
38. Ito Y, Miyauchi A, Ishikawa H, Hirokawa M, Kudo T, et al. (2011) Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma: difference in clinicopathological features of FAP-associated and sporadic patients. Endocr J 58: 685-689.
39. Miyauchi A, Kudo T, Hirokawa M, Ito Y, Kihara M, et al. (2013) Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J 2: 57-64.
40. Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, et al. (2010) Prognostic significance of Ki-67 labeling index in papillary thyroid carcinoma. World J Surg 34: 3015-3021.
41. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, et al. (2013) Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid Mar 17 [Epub ahead of print]
42. Xing M, Alzaharani AS, Carson KA, Viola D, Elisei R, et al. (2013) Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309: 1493-1501.
43. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, et al. (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56: 89-97.
44. Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, et al. (2013) BRAFV600E mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg in press.
45. Miyauchi A, Kudo T, Kihara M, Higashiyama T, Ito Y, et al. (2013) Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocr J 60: 415-421.
46. Herrera MF, Lopez-Graniel CM, Saldana J, Gamboa-Dominguez A, Richaud-Patin Y, et al. (1996) Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors. World J Surg 20: 94-99.
47. Brownlie BJ, Turner J, Abdelaal AS (2012) Deaths due to differentied thyroid cancer: a South Island, New Zealand experience: 1984-2009. N Z Med J 125: 13-21.
48. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY (2007) Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol 14: 730-738.
49. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, et al. (2004) Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocr Relat Cancer 11: 131-139.
50. Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, et al. (2008) Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol 15: 1518-1522.
51. Silronen P, Louhimo J, Nordling S, RIstimaki A, Maenpaa H, et al. (2005) Prognostic factors in papillary thyroid cander: an evaluation of 601 consecutive patients. Tumour Biol 26: 57-64.
52. Sciuto R, Romono L, Rea S, Marandino F, Sperduti I, et al. (2009) Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 20: 1728-1735.
53. Krausz Y, Uziely B, Karger H, Isacson R, Catane R, et al. (1993) Recurrence-associated mortality in patients with differentiated thyroid carcinoma. J Surg Oncol 52: 164-168.
54. Erichhorn W, Tabler H, Lippoid R, Lochmann M, Schreckenberger M, et al. (2003) Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 13: 949-958.
55. Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, et al. (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph node, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36: 1274-1278.
56. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, et al. (2011) Prognostic impact of serum thyroglobulin doubine-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21: 707-716.
57. Ronga G, Filesi M, Montesano T, Nicola AD, Pace C (2004) Lung metastases from differentiated thyroid carcinoma. Q J Nucl Med Mol Imaging 48: 12-19.
58. Mihailovic J, Stefanovic L, Malesevic M, Markoski B (2009) The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastasis. Thyroid 19: 227-232.
59. Kim TH, Chung KW, Lee YJ, Park CS, Lee EK, et al. (2010) The effect of external beam radiotherapy volume on locoregional control in patients with locoregional advanced or recurrent nonanaplastic thyroid cancer. Radiat Oncol 5: 69.
60. Cho JS, Yoon JH, Park MH, Shin SH, Jegal YJ, et al. (2012) Age and prognosis of papillary thyroid carcinoma: retrospective stratification into three groups. J Korean Surg Soc 83: 259-266.
61. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, et al. (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34: 1222-1231.
62. Sugitani I, Fujimoto Y (1999) Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46: 209-216.
63. Ito Y, Fukushima M, Kihara M, Takamura Y, Kobayashi K, et al. (2012) Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Endocr J 59: 457-464.
64. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
65. Franssila KO, Harasch HR (1986) Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland. Cancer 58: 715-719.
66. Lang W, Borrusch H, Bauer L (1988) Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol 90: 72-76.
67. Martinez Tello FJ, Martinez-Cabruia R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carvavilla C (1993) Occult carcinoma of the thyroid. A systematic study from Spain of two series performed with different methods. Cancer 71: 4022-4029.